报告导读： 全自动血细胞分析仪是一种现代化医疗设备，利用光学、计算机、生物技术等手段，对血液中的细胞成分进行快速自动分析、计数和分类。其核心功能包括 血细胞计数、分类及参数分析，适用于临床血液检测，为疾病诊断、治疗监测及科研提供关键数据支持。按白细胞分类水平，可分为二分类、三分类和五分 类等类型。近年来，随着人们健康意识的提高，门诊健康检查人数不断增加，2023年达到5.25亿人，同比增长4.37%。这直接推动了血液检测设备的需求增 长。2024年，中国全自动血细胞分析仪市场规模为21.5亿元，同比增长9.69%。技术不断创新，检测参数更丰富，精度和速度进一步提高，智能化功能显著 提升。 基于此，依托智研咨询旗下全自动血细胞分析仪行业研究团队深厚的市场洞察力，并结合多年调研数据与一线实战需求，智研咨询推出《2025-2031年中国 全自动血细胞分析仪行业市场现状调查及产业趋势研判报告》。本报告立足全自动血细胞分析仪新视角，聚焦行业核心议题——变化趋势（怎么变）、用户 需求（要什么）、投放选择（投向哪）、运营方法（如何投）及实践案例（看一看），期待携手行业伙伴，共谋行业发展新格局、新机遇，推动全自动血细 胞分析 ...

Industry Overview - The fully automated blood cell analyzer is an essential diagnostic tool in healthcare institutions, playing a crucial role in disease diagnosis, treatment monitoring, and health check-ups. Its rapid detection speed and accurate results meet the growing demand for medical testing, providing strong support for clinical diagnosis [1][7] - The market size of China's fully automated blood cell analyzer industry is projected to reach 2.15 billion yuan in 2024, with a year-on-year growth of 9.69% [1][7] - Recent technological innovations have enhanced the detection parameters, precision, and speed of these devices. High-end models now feature intelligent functions such as automatic sampling, dilution, and retesting, significantly improving testing efficiency and accuracy [1][7] Industry Chain - The upstream of the fully automated blood cell analyzer industry includes electronic components like sensors, integrated circuits, and displays, as well as optical components such as lasers and lenses, mechanical parts, reagents, consumables, and software systems. The midstream involves the manufacturing of the analyzers, while the downstream applications are found in hospitals, clinics, health check centers, and research institutions [3] Market Demand - With rising living standards and increased health awareness, there is a growing willingness among people to undergo health checks. In 2023, the number of outpatient health checks in China reached 525 million, a year-on-year increase of 4.37%. This increase directly drives the demand for blood testing, expanding the market for fully automated blood cell analyzers [4] Relevant Policies - The Chinese medical device industry is experiencing rapid development driven by policy support and technological innovation. The National Health Commission issued a quality standard for clinical blood testing projects in November 2024, providing systematic requirements for fully automated blood cell analyzers in terms of detection accuracy, quality control, and equipment performance [6] Key Enterprises - The industry is dominated by domestic companies, with a high market concentration. Technological iteration and policy support are key competitive factors. Major players include Mindray Medical, which occupies the high-end market with its BC-7500 series, and companies like Dymind and YuliTech that penetrate the grassroots market with cost-effective solutions [7][9] Industry Development Trends 1. **Technological Integration**: The future of fully automated blood cell analyzers will focus on higher precision, faster speeds, and greater intelligence. The integration of AI, big data, and IoT will enhance data analysis and processing capabilities, enabling features like automatic anomaly detection and remote diagnostics [10] 2. **Market Expansion**: The continuous growth of the Chinese medical market and supportive policies will sustain the demand for fully automated blood cell analyzers, particularly in grassroots medical institutions and central-western regions. Domestic products are increasingly replacing imports due to improved performance and cost-effectiveness [11][12] 3. **Intensified Competition**: The industry will face heightened competition, leading to consolidation through mergers and acquisitions. This will optimize resource allocation and promote technological innovation. Additionally, international expansion will become a significant focus as domestic companies enhance their technical capabilities and brand influence [13]